Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
Partner
CAR-T (Off-the-Shelf)
T-ALL/LBL
WU-CART-007
Memory NK (1:1)
AML
WU-NK-101
AML
WU-NK-101 Asia (China, HK, Macao, Taiwan & Singapore)
Memory NK (Off-the-Shelf)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen to Present at the Upcoming Jefferies Cell & Genetic Medicine Summit
SAINT LOUIS, MO and SAN DIEGO, CA, September 23, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022
-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic…
Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors
Cell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO,…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design